JP2008509928A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509928A5
JP2008509928A5 JP2007525838A JP2007525838A JP2008509928A5 JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5 JP 2007525838 A JP2007525838 A JP 2007525838A JP 2007525838 A JP2007525838 A JP 2007525838A JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5
Authority
JP
Japan
Prior art keywords
use according
methylene
tetraazacyclotetradecanyl
phenylenebis
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007525838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509928A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/028783 external-priority patent/WO2006020891A2/en
Publication of JP2008509928A publication Critical patent/JP2008509928A/ja
Publication of JP2008509928A5 publication Critical patent/JP2008509928A5/ja
Withdrawn legal-status Critical Current

Links

JP2007525838A 2004-08-13 2005-08-11 前駆/幹細胞を動員するためのケモカインの組み合わせ Withdrawn JP2008509928A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60136704P 2004-08-13 2004-08-13
PCT/US2005/028783 WO2006020891A2 (en) 2004-08-13 2005-08-11 Chemokine combinations to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
JP2008509928A JP2008509928A (ja) 2008-04-03
JP2008509928A5 true JP2008509928A5 (OSRAM) 2008-10-09

Family

ID=35908186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525838A Withdrawn JP2008509928A (ja) 2004-08-13 2005-08-11 前駆/幹細胞を動員するためのケモカインの組み合わせ

Country Status (9)

Country Link
US (1) US20060035829A1 (OSRAM)
EP (1) EP1796716A4 (OSRAM)
JP (1) JP2008509928A (OSRAM)
CN (1) CN101094684A (OSRAM)
AU (1) AU2005272653A1 (OSRAM)
BR (1) BRPI0514343A (OSRAM)
CA (1) CA2577046A1 (OSRAM)
TW (1) TW200608991A (OSRAM)
WO (1) WO2006020891A2 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) * 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
CN101389329A (zh) * 2006-02-24 2009-03-18 健赞股份有限公司 增加血流和/或促进组织再生的方法
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
EP2068868A2 (en) * 2006-08-02 2009-06-17 Genzyme Corporation Combination therapy
EP2094274A4 (en) * 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
CN102481332A (zh) * 2009-06-14 2012-05-30 拜欧肯疗法有限公司 用于提高血小板水平的肽疗法
RU2638802C2 (ru) 2011-05-16 2017-12-15 Джензим Корпорейшн Применение антагонистов cxcr4
CN103159690B (zh) * 2011-12-14 2015-03-25 朱靖华 对称大环胺化合物的结晶形式
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
RU2650962C2 (ru) 2012-06-07 2018-04-18 Чилдрен'З Хоспитал Лос Анджелес Способы лечения нейтропении с применением ретиноидных агонистов
SG11201508027PA (en) * 2013-02-28 2015-11-27 Harvard College Methods and compositions for mobilizing stem cells
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
AU2016269839B2 (en) * 2015-06-03 2021-07-08 The University Of Queensland Mobilizing agents and uses therefor
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
JP2019507596A (ja) * 2016-02-26 2019-03-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 生着性の高い造血幹細胞
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
JP7352807B2 (ja) 2017-04-12 2023-09-29 マジェンタ セラピューティクス インコーポレイテッド アリール炭化水素受容体アンタゴニスト及びその使用
EP3704232A1 (en) 2017-10-31 2020-09-09 Magenta Therapeutics, Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
AU2018358054A1 (en) 2017-10-31 2020-05-07 Magenta Therapeutics Inc. Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
BR112020011186A2 (pt) * 2017-12-06 2020-11-17 Magenta Therapeutics, Inc. regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20200338132A1 (en) 2018-01-03 2020-10-29 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
MX2022013493A (es) 2020-04-27 2023-02-22 Magenta Therapeutics Inc Metodos y composiciones para transducir celulas madre y progenitoras hematopoyeticas in vivo.
WO2022197776A1 (en) 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN116789639A (zh) * 2022-03-14 2023-09-22 上海医药工业研究院有限公司 Mavorixafor的纯化方法、其盐及有关物质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
DE69433301T2 (de) * 1993-06-08 2004-09-09 Smithkline Beecham Corp. Methoden zur erhöhung der biologischen aktivität von chemokinen
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
WO1995016464A1 (en) * 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
JP2003516984A (ja) * 1999-12-17 2003-05-20 アノーメッド・インコーポレイテッド ケモカインレセプターを結合する複素環式化合物
BR0113932A (pt) * 2000-09-15 2003-06-24 Anormed Inc Compostos heterocìclicos que se ligam ao receptor da quimiocina
SG126006A1 (en) * 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP1317445B1 (en) * 2000-09-15 2009-03-11 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU2002211393B2 (en) * 2000-09-29 2007-06-28 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
EP1385865A4 (en) * 2001-04-03 2005-05-25 Applera Corp ISOLATED HUMAN KINASEPROTEINS, NUCLEIC ACID MOLECULES CODING FOR HUMAN KINASEPROTEINS AND THEIR USES
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
PT2371361T (pt) * 2001-07-31 2019-09-10 Genzyme Corp Métodos para mobilizar células progenitoras/estaminais
CN100463962C (zh) * 2001-12-07 2009-02-25 图尔金株式会社 嵌合蛋白质的表型筛选
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
EP1615633B1 (en) * 2003-04-22 2012-08-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2005059107A2 (en) * 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds

Similar Documents

Publication Publication Date Title
JP2008509928A5 (OSRAM)
US20230167076A1 (en) 1,2,4-Oxadiazole Derivatives as Immunomodulators
CA2455559A1 (en) Methods to mobilize progenitor/stem cells
ES2983582T3 (es) Composiciones bioortogonales
JP2014513727A5 (OSRAM)
JP2008528658A5 (OSRAM)
JP2008195730A5 (OSRAM)
JP2017533922A5 (OSRAM)
JP2014528467A5 (OSRAM)
JP2016505586A5 (OSRAM)
JP2017511360A5 (OSRAM)
JP2011006428A5 (OSRAM)
CA2361587A1 (en) Methods and compositions to enhance white blood cell count
JP2022095872A5 (OSRAM)
CN101495115A (zh) 组合治疗
RU2006132071A (ru) Производные антраниловой кислоты, способы их получения и применение
US20240158445A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
RU2014124171A (ru) Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе
TW200607508A (en) Powder formulations for inhalation, comprising enantiomerically pure beta agonists
CN101175490B (zh) 循环障碍改善剂
JP2008520682A (ja) ヒストンデアセチラーゼ阻害剤およびその使用方法
JP2005527479A5 (OSRAM)
ES2547726T3 (es) Nueva enzima altamente funcional que tiene especificidad de sustrato modificada
WO2008113095A1 (en) Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
CA2954175A1 (en) Compositions and methods to improve adoptive cell therapies